Answers are grounded in this paper and cite their sources.
Symptoms of Parkinson's disease (PD) are caused by a slowly progressive degeneration of dopaminergic neurons in the substantia nigra. The hematopoietic granulocyte-colony stimulating factor (G-CSF) plays a crucial role in controlling the number of neutrophil progenitor cells. Its function is mediated via the G-CSF receptor, which is expressed not only on hematopoietic cells but also by dopaminergic neurons of the substantia nigra (SN), suggesting that G-CSF might be neuroprotective for dopaminergic neurons and a candidate molecule for the treatment of PD. Recently, we provided prove-of-principle that daily G-CSF (Filgrastim) application significantly reduces dopaminergic cell death in in vitro and in vivo models of PD. Indicating preservation of dopaminergic terminals in the striatum, G-CSF alleviated striatal dopamine depletion after MPTP application in G-CSF-treated mice. Consequently, we tested pharmacokinetically improved G-CSF variants (Pegfilgrastim), with an extended serum half-life compared to conventional G-CSF. Subcutaneous application of Pegfilgrastim only every 3rd day rescued about 50% of dopaminergic substantia nigra neurons from MPTP – induced apoptosis in vitro and in vivo. Thus, pharmacologically modified forms of G-CSF with a longer half-life could improve patient compliance and acceptance of G-CSF as a neuroprotective therapy for PD.
No takes yet. Share an insight, caveat, or question.
Frank et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: